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HIV-­1-­infected  people  who  take  drugs  that  suppress  viremia  to  undetectable  levels  are  
protected   from   developing   AIDS.   Nonetheless,   these   individuals   have   chronic  
inflammation   associated   with   heightened   risk   of   cardiovascular   pathology.   HIV-­1  
establishes  proviruses  in  long-­lived  CD4+  memory  T  cells,  and  perhaps  other  cell  types,  
that   preclude  elimination   of   the   virus   even  after   years   of   continuous  antiviral   therapy.  
Though  the  majority  of  proviruses  that  persist  during  antiviral   therapy  are  defective  for  
production  of  infectious  virions,  many  are  expressed,  raising  the  possibility  that  the  HIV-­
1  provirus  or  its  transcripts  contribute  to  ongoing  inflammation.  Here  we  found  that  the  
HIV-­1   provirus   activated   innate   immune   signaling   in   isolated   dendritic   cells,  
macrophages,  and  CD4+  T  cells.  Immune  activation  required  transcription  from  the  HIV-­
1   provirus   and   expression   of   CRM1-­dependent,   Rev-­dependent,   RRE-­containing,  
unspliced  HIV-­1  RNA.   If   rev  was   provided   in   trans,   all  HIV-­1   coding   sequences  were  
dispensable  for  activation  except  those  cis-­acting  sequences  required  for  replication  or  
splicing.  These  results  indicate  that  the  complex,  post-­transcriptional  regulation  intrinsic  
to  HIV-­1  RNA   is  detected  by   the   innate   immune  system  as  a  danger  signal,  and   that  
drugs  which  disrupt  HIV-­1  transcription  or  HIV-­1  RNA  metabolism  would  add  qualitative  
benefit  to  current  antiviral  drug  regimens.     
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INTRODUCTION  
Drugs  that  block  activity  of  the  three  HIV-­1  enzymes  -­  reverse  transcriptase,  integrase,  
and   protease   -­   potently   suppress   HIV-­1   viremia   and   protect   infected   people   from  
developing   AIDS   (Günthard   et   al.,   2016).   Despite   effective   antiviral   therapy,   many  
patients   have   systemic   inflammation   associated   with   increased   risk   of   cardiovascular  
pathology   (Brenchley  et  al.,  2006;;  Freiberg  et  al.,  2013;;  Sinha  et  al.,  2016).  Plausible  
explanations   for   this   inflammation   include   ongoing   T   cell   dysfunction,   disruption   of  
intestinal   epithelium   integrity,   lymphatic   tissue   fibrosis,   antiviral   drug   toxicity,   and   co-­
morbid   infections   such   as   cytomegalovirus   (Brenchley   et   al.,   2006;;  Hunt   et   al.,   2011;;  
Sinha  et  al.,  2016).  
Inflammation  may  also  be  maintained  by  HIV-­1  itself.  HIV-­1  is  not  eliminated  from  
the  body  after  years  of  continuous  suppressive  therapy  and  viremia  inevitably  rebounds  
upon  drug  cessation  (Davey  et  al.,  1999).  This  is  because  HIV-­1  establishes  a  provirus  
in   long-­lived   CD4+   memory   T   cells   and   perhaps   other   cell   types   that   include   tissue-­
resident  myeloid  cells  (Jiang  et  al.,  2015;;  Kandathil  et  al.,  2016;;  Siliciano  et  al.,  2003).  
Proviruses   are   obligate   replication   intermediates   that   result   from   the   integration   of  
retroviral   cDNA   into   chromosomal   DNA   to   become   permanent,   heritable   genetic  
elements   in   infected   cells   (Engelman   and   Singh,   2018).   Though   the   vast   majority   of  
proviruses   that   persist   in   the   presence   of   antiviral   therapy   are   defective   for   the  
production  of  infectious  virus  (Bruner  et  al.,  2016),  2-­18%  express  HIV-­1  RNA  (Wiegand  
et  al.,  2017).  Here  we  assessed  HIV-­1  proviruses  and  their  gene  products  for  the  ability  
to  contribute  to  chronic  inflammation.         
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RESULTS    
To  determine   if  HIV-­1  proviruses  activate   innate   immune  signaling,  human  blood  cells  
were  transduced  with  single-­cycle  vectors,  either  a  full-­length,  single-­cycle  HIV-­1  clone  
with  a   frameshift   in  env  and  eGFP   in  place  of  nef   (HIV-­1-­GFP)  (He  et  al.,  1997),  or  a  
minimal   3-­part   lentivector   encoding   GFP   (Fig.   1a   and   Table   1)   (Pertel   et   al.,   2011).  
Monocyte   derived   dendritic   cells   (DCs)   were   challenged   initially   since   HIV-­1  
transduction   of   these   specialized   antigen-­presenting   cells   activates   innate   immune  
signaling   (Berg   et   al.,   2012;;   Gao   et   al.,   2013;;   Landau,   2014;;   Manel   et   al.,   2010;;  
Rasaiyaah   et   al.,   2013).   To   increase   the   efficiency   of   provirus   establishment,   vectors  
were  pseudotyped  with  the  vesicular  stomatitis  virus  glycoprotein  (VSV  G)  and  delivered  
concurrently  with  virus-­like  particles  (VLPs)  bearing  SIVMAC251  Vpx  (Fig.  1b)  (Goujon  et  
al.,  2006;;  Pertel  et  al.,  2011).  Transduction  efficiency,  as  determined  by  flow  cytometry  
for  GFP-­positive  cells,  was  30-­60%  (Fig.  1b),  depending  on  the  blood  donor.  
DCs  matured  in  response  to  HIV-­1-­GFP  transduction,  as  indicated  by  increased  
mean   fluorescence   intensity   of   co-­stimulatory   or   activation  molecules,   including  HLA-­
DR,  CD80,  CD86,  CD40,  CD83,  CCR7,  CD141,   ISG15,  MX1,  and   IFIT   (Sousa,  2006)  
(Fig.  1b,  c).  Maturation  was  evident  among  both  GFP  positive  and  negative  cells  (Fig.  
1b),   the   latter   resulting   from  activation   in   trans   by   type   1   IFN   as   several   others   have  
shown  (Manel  et  al.,  2010;;  Rasaiyaah  et  al.,  2013).  Identical  results  were  obtained  with  
full-­length,  single-­cycle  vectors  generated  from  primary,  transmitted/founder  clones  that  
were  derived  by  single  genome  sequencing,  HIV-­1AD17  (Parrish  et  al.,  2013),  HIV-­1Z331M-­
TF  (Deymier  et  al.,  2015),  and  HIV-­1ZM249M  (Salazar-­Gonzalez  et  al.,  2009),  the  first  virus  
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being  clade  B,  the  other  two  clade  C  (Fig.  1d).  A  single  cycle  HIV-­2  vector  also  induced  
maturation,  indicating  that  this  innate  response  was  not  unique  to  HIV-­1  (Fig.  1e).      
DCs   matured   when   HIV-­1-­GFP   transduction   efficiency   was   augmented   with  
nucleosides  (Reinhard  et  al.,  2014),  rather  than  with  SIV  VLPs,  indicating  that  Vpx  was  
not   required   for   maturation   (Fig.   1f).   DCs   were   then   challenged   with   replication-­
competent   HIV-­1   bearing   CCR5-­tropic   Env,   either   T   cell-­tropic   or   macrophage-­tropic  
(Granelli-­Piperno  et  al.,  1998),  with  or  without  Vpx-­VLPs  (Fig.  1g).  The  percent  of  cells  
transduced  by  vector  bearing  either  Env  increased  with  Vpx,  though  DC  maturation  was  
observed  under  all  conditions,  even  among  the  very  few  DCs  transduced  by  T  cell-­tropic  
env  (see  inset  of  Fig.  1g).  These  results  indicate  that  neither  VSV  G,  nor  Vpx,  nor  high-­
titer  infection,  was  required  for  DC  maturation.    
In   response   to   transduction  with  HIV-­1-­GFP,  steady-­state  CXCL10,   IFNB1,  and  
IL15  mRNAs  reached  maximum  levels  at  48  hrs,  increasing  31,000-­,  92-­,  and  140-­fold  
relative   to  mock-­treated  cells,   respectively   (Fig.  1h,   i).  Correspondingly,   IFNα2,  CCL7,  
IL-­6,  CXCL10,  and  TNFα  proteins  accumulated  in  the  supernatant  (Fig.  1j).  In  contrast  
to  the  results  with  HIV-­1-­GFP,  there  were  no  signs  of  maturation  after  transduction  with  
the  3-­part  minimal  lentivector  (Fig.  1b,  h,  j).  
To   determine   if   early   stages   in   the  HIV-­1   replication   cycle   were   necessary   for  
maturation,   reverse   transcription   was   inhibited   by   nevirapine   (NVP)   or   the   HIV-­1   RT  
mutant   D185K/D186L,   and   integration   was   inhibited   with   raltegravir   or   the   HIV-­1   IN  
mutant  D116A   (Tables  1  and  2),  as  previously  described   (De   Iaco  and  Luban,  2011).  
Each  of  these  four  conditions  abrogated  maturation,  as  indicated  by  cell  surface  CD86  
(Fig.   2a)   and   steady-­state  CXCL10   mRNA   (Fig.   2b).  When   integration   was   inhibited,  
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CXCL10  mRNA   increased   in   response   to   challenge  with  HIV-­1-­GFP,   but   levels  were  
nearly  1,000  times  lower  than  when  integration  was  not  blocked  (Fig.  2b).  
HIV-­1  virion  RNA  and  newly  synthesized  viral  cDNA  are  reported  to  be  detected  
by   RIG-­I   and   by   cGAS,   respectively   (Berg   et   al.,   2012;;   Gao   et   al.,   2013).   Signal  
transduction  downstream  of  both  sensors  requires  TBK1  and  IRF3.  The  TBK1  inhibitor  
BX795   (Table  2)  blocked  DC  maturation   in   response   to   cGAMP  but  had  no  effect   on  
maturation  after  HIV-­1-­GFP  transduction  (Fig.  2c).  Moreover,  IRF3  knockdown  (Table  1)  
(Pertel  et  al.,  2011)  suppressed  activation  of  CD86  or  ISG15  in  response  to  cGAMP,  but  
not  in  response  to  HIV-­1  transduction  (Fig.  2c).  Similarly,  no  effect  on  HIV-­1-­induced  DC  
maturation  was  observed  with  knockdown  of  IRF1,  5,  7,  or  9,  or  of  STAT1  or  2,  or  TAK1  
(Table  1)  (Pertel  et  al.,  2011),  or  of  pharmacologic  inhibition  of  CypA,  PKR,  c-­Raf,  IkBa,  
NF-­kB,   MEK1+2,   p38,   JNK,   Caspase   1,   pan-­Caspases,   ASK1,   eIF2a,   TBK1,   IKKe,  
TAK1,   or   NLRP3   (Table   2).   Under   the   conditions   used   here,   then,   DC   maturation  
required   reverse   transcription   and   integration   but   was   independent   of   most   well-­
characterized  innate  immune  signaling  pathways.  
Completion   of   the   HIV-­1   integration   reaction   requires   cellular   DNA   repair  
enzymes   (Craigie   and   Bushman,   2012).   That   DCs   did   not   mature   in   response   to  
transduction  with  minimal  lentivectors  (Fig.  1b,  i,   j)   indicates  that  activation  of  the  DNA  
repair  process  is  not  sufficient,  and  that  transcription  from  the  HIV-­1-­GFP  provirus  must  
be   necessary   for   maturation.   Indeed,   gag   expression   from   an   integrated   vector   has  
been  reported  to  be  necessary  for  DC  maturation  (Manel  et  al.,  2010).  To  determine  if  
any   individual  HIV-­1  proteins  were  sufficient   to  mature  DCs,  a  minimal   lentivector  was  
used   to   express   codon   optimized   versions   of   each   of   the   open   reading   frames  
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possessed   by   HIV-­1-­GFP   (Fig.   2d,   Table   1).   Among   these   vectors   was   a   gag-­
expression  vector  that  produced  as  much  p24  protein  as  did  HIV-­1-­GFP  (Fig.  2d).  None  
of  these  vectors  matured  DCs  (Fig.  2d).  
HIV-­1-­GFP  was  then  mutated  to  determine  if  any  protein  coding  sequences  were  
necessary   for  DC  maturation.  For   these  and  any  subsequent  experiments   in  which  an  
essential  viral  component  was  disrupted  within  HIV-­1-­GFP,   the   factor   in  question  was  
provided   in   trans,   either   during   assembly   in   transfected   HEK293   cells,   or   within  
transduced  DCs,  as  appropriate  (see  Methods).  Mutations  that  disrupted  both  gag  and  
pol,  either  a  double  frameshift  in  gag,  or  a  mutant  in  which  the  first  14  ATGs  in  gag  were  
mutated,  abolished  synthesis  of  CA  (p24)  yet   retained   full  maturation  activity   (Fig.  2e,  
Table   1).   Deletion   mutations   encompassing   gag/pol,   vif/vpr,   vpu/env,   or   nef/U3-­LTR,  
each  designed  so  as  to  leave  cis-­acting  RNA  elements  intact,  all  matured  DCs  (Fig.  2f  
and  Table  1).  These  results  indicate  that  these  HIV-­1-­GFP  RNA  sequences,  as  well  as  
the  proteins  that  they  encode,  were  not  required  for  DC  maturation.  
Tat   and   Rev   coding   sequences   were   individually   disrupted   by   combining   start  
codon   point   mutations   with   nonsense   codons   that   were   silent   with   respect   to  
overlapping   reading   frames   (Table   1).   Neither   Δtat   nor   Δrev   matured   DCs   upon  
transduction  (Fig.  2g).  However,  DCs  matured  upon  co-­transduction  of  Δtat  and  Δrev,  or  
when  minimal  lentivectors  expressing  codon-­optimized  Tat  and  Rev  were  co-­transduced  
in   trans   (Fig.  2g).  These   results   indicate   that   the  maturation  defect  with   the   individual  
vectors  was  due  to  disruption  of  Tat  and  Rev  function,  and  not  due  to  a  cis-­acting  defect  
of  the  mutant  RNA.  
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The  minimal  3-­part  lentivector  expressed  GFP  from  a  heterologous  promoter  and  
had  a  deletion  mutation  encompassing  the  essential,  cis-­acting  TATA  box  and  enhancer  
elements   (Zufferey   et   al.,   1998),   as   well   as   in   the   trans-­acting   tat   and   rev,   that  
inactivated  the  promoter  in  the  proviral  5’  LTR  (Fig.  1a).  To  test  the  importance  of  LTR-­
driven   transcription   for   DC   maturation   by   the   HIV-­1   provirus,   the   HIV-­1   LTR   was  
restored   in   the  minimal  vector   (Fig.  2h  and  Table  1);;   in  addition,  GFP  was   inserted   in  
place  of  gag  as  a  marker  for  LTR  expression,  and  the  heterologous  promoter  was  used  
to  drive   tat,   rev,  or  both  genes  separated  by  P2A  coding  sequence  (Fig.  2h).  None  of  
the  LTR-­driven,  minimal  vectors  matured  DCs  (Fig.  2h).  
To  determine  if  tat  was  necessary  for  DC  maturation,  tat  and  TAR  were  mutated  
in   HIV-­1-­GFP   and   the   LTR   promoter   was   modified   to   be   tetracycline-­inducible,   as  
previously  described  (Das  and  Berkhout,  2016)  (Tet-­HIV-­1  in  Fig.  3a  and  Table  1).  The  
doxycycline-­dependent   reverse   transactivator   (rtTA)   was   delivered   in   trans   by  
lentivector.  In  the  presence  of  doxycycline  (Table  2),  Tet-­HIV-­1  and  rtTA  matured  DCs  
when  given  in  combination,  but  neither  vector  matured  DCs  when  given  in  isolation  (Fig.  
3a).  Additionally,  the  magnitude  of  cell  surface  CD86  was  dependent  on  the  doxycycline  
concentration,   indicating   that   maturation   was   dependent   on   the   level   of   HIV-­1  
transcription   (Fig.   3b).   These   results   demonstrated   that   tat   was   not   required   for  
maturation,  so  long  as  the  provirus  was  expressed.    
To   ascertain   whether   rev   was   necessary   for   DC   maturation,   the   RTE   from   a  
murine   intracisternal   A-­particle   retroelement   (IAP),   and   the   CTE   from   SRV-­1,   were  
inserted  in  place  of  nef  (HIV-­RTE/CTE  in  Fig.  3c  and  Table  1)  (Smulevitch  et  al.,  2006).  
Each   of   these   elements   utilizes   the   NXF1   nuclear   RNA   export   pathway,   thereby  
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bypassing   the   need   for   CRM1   and   rev   (Fornerod   et   al.,   1997).   p24   levels   with   this  
construct   were   similar   to   those   of   HIV-­1-­GFP,   indicating   that   unspliced   RNA   was  
exported  from  the  nucleus  at  least  as  well  as  with  Rev  (Fig.  3c).  Nonetheless,  the  HIV-­
RTE/CTE  vector  did  not  mature  DCs  (Fig.  3c),  indicating  that  maturation  was  dependent  
upon  rev  and  CRM1-­mediated  RNA  export.  Consistent  with  this  conclusion,  the  CRM1  
inhibitor   leptomycin  B   (Table   2)   abrogated  DC  maturation   by  HIV-­1-­GFP   (Fig.   3d).   In  
contrast,   leptomycin   B   had   no   effect   on   DC   maturation   in   response   to   Sendai   virus  
infection  (Fig.  3e).   ISG15  was  used   to  monitor  maturation   in   these  experiments  since,  
as   previously   reported   for   DCs,   leptomycin   B   altered   background   levels   of   CD86  
(Chemnitz  et  al.,  2010).  
To  determine  if  innate  immune  detection  of  HIV-­1  was  unique  to  DCs,  monocyte-­
derived  macrophages   and   CD4+   T   cells   were   examined.   In   response   to   transduction  
with  HIV-­1-­GFP,  macrophages   upregulated  CD86,   ISG15,   and  HLA-­DR,   and  CD4+   T  
cells  upregulated  MX1,  IFIT1,  and  HLA-­DR  (Fig.  4a).  DCs,  macrophages,  and  CD4+  T  
cells   were   then   transduced   side-­by-­side   with   mutant   constructs   to   determine   if   the  
mechanism  of  innate  immune  activation  was  similar  to  that  in  DCs.  As  with  DCs,  HIV-­1-­
GFP  bearing  the  Δgag/pol  deletion  activated  macrophages  and  CD4+  T  cells  (Fig.  4b).  
Also   in  agreement  with   the  DC  results,  neither   the  minimal   lentivector,  nor  HIV-­1-­GFP  
bearing  mutations  in  integrase,  tat,  or  rev,  matured  any  of  the  three  cell  types  (Fig.  4b).    
CD4+  T  cells  were  infected  with  either  macrophage-­tropic  or  T  cell-­tropic  HIV-­1  to  
determine  whether  replication-­competent  HIV-­1  was  similarly  capable  of  innate  immune  
activation   in   these   cells,   in   the   absence   of   VSV   G.   As   with   DCs,   innate   immune  
activation,   as   detected   by   MX1   and   ISG15   upregulation,   was   observed   in   cells  
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productively  infected  with  HIV-­1,  but  not  with  minimal  lentivector  (Fig.  4c).  Finally,  to  test  
the   effect   of   HIV-­1   proviral   RNA   on   non-­activated   T   cells,   CD4+   T   cells   were   co-­
transduced  with  Tet-­HIV-­1  and  the  rtTA3  vector,  and  cultured  for  9  days  in  the  absence  
of  stimulation.  Upon  doxycycline  treatment,  T  cells  expressed  GFP  and  MX1  (Fig.  4d).  
As  in  DCs,  dose-­dependent  activation  was  observed  with  doxycycline  (Fig.  4d).  These  
data   indicate   that   innate   immune   activation   by  HIV-­1,   in   all   three   cell   types,   requires  
integration,  transcription,  and  Rev-­dependent,  HIV-­1  intron-­containing  RNA.  
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DISCUSSION  
The  HIV-­1  LTR  generates  a  single  primary  transcript  that  gives  rise  to  over  100  
alternatively   spliced   RNAs   (Ocwieja   et   al.,   2012).   The   full-­length,   unspliced,   intron-­
bearing   transcript  acts  as  viral  genomic  RNA   in   the  virion  and  as  mRNA   for  essential  
gag-­   and   pol-­encoded   proteins.   Expression   of   the   unspliced   transcript   requires  
specialized  viral  and  cellular  machinery,  HIV-­1  Rev  and  CRM1  (Fornerod  et  al.,  1997),  
in   order   to   escape   from   the   spliceosome.   Results   here   indicate   that   unspliced   or  
partially  spliced  HIV-­1  RNA  is  detected  by  human  cells  as  a  danger  signal,  as  has  been  
reported  for  inefficiently  spliced  mRNAs  from  transposable  elements  in  distantly  related  
eukaryotes   (Dumesic   et   al.,   2013).   Transposable  elements   are  mutagenic   to   the  host  
genome   and   it   stands   to   reason   that   molecular   features   such   as   transcripts   bearing  
multiple,   inefficient   splice   signals   characteristic   of   retrotransposons,   would   activate  
innate  immune  signaling  pathways.  
HIV-­1   genomic  RNA   contains   extensive   secondary   and   higher   order   structures  
that   could   be   detected   by   innate   immune   sensors.   Our   knockdown   of   IRF3   and  
inhibition   of   TBK1,   both   required   for   signal   transduction   of   the   RNA   sensors   RIG-­I,  
MDA5,  and  TLR3,  did  not   impede  HIV-­1  maturation  of  DCs   (Figure  2c).  Furthermore,  
we   suppressed   an   extensive   list   of   innate   signaling   pathways   and   sensors   including  
knockdowns   of   IRF’s   1,   5,   7,   and   9,   STAT’s   1   and   2,   or   of   TAK1,   as   well   as  
pharmacologic  inhibition  of  CypA,  CRM1,  PKR,  c-­Raf,  IkBa,  NF-­kB,  MEK1+2,  p38,  JNK,  
Caspase   1,   pan-­Caspases,   ASK1,   eIF2a,   IKKe,   TAK1,   or   NLRP3   (Table   2).   None   of  
these   perturbations   had   any   effect   on   limiting   innate   immune   activation   by   HIV-­1,  
suggesting   requirement   for   an   alternative   detection   mechanism.   Such   mechanisms  
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might   include   uncharacterized   RNA   sensors,   direct   detection   of   stalled   splicing  
machinery,  or  overload  of  the  CRM1  nuclear  export  pathway  itself.  
The  replication  competent  HIV-­1  reservoir   in  memory  CD4+  T  cells  has  a  44  wk  
half-­life   and   thus  patients  must   take  antiviral  medication   for   life   (Crooks  et   al.,   2015).  
Long-­lived,   replication   competent   HIV-­1   reservoirs   in   other   cell   types   have   not   been  
clearly  demonstrated,  but  these  may  also  contribute  to  the  HIV-­1  reservoir  (Kandathil  et  
al.,  2016).  The  common  genetic  determinants   in  HIV-­1   for  maturation  of  CD4+  T  cells,  
macrophages,   and   DCs   suggests   that   HIV-­1   is   detected   by   a   mechanism   that   is  
conserved  across  cell   types,  and  that  this  mechanism  would  be  active  in  any  cell   type  
that  possesses  a  transcriptionally  active  provirus.  Data  here  show  that  proviruses  need  
not  be   replication  competent   to  contribute   to   inflammation.  Rather,  HIV-­1   transcription  
and   export   of   unspliced   RNA,   regardless   of   replication   competence,   is   sufficient   to  
induce   immune   activation.   Consistent   with   our   findings,   T   cell   activation   correlates  
directly  with   the   level   of   cell-­associated  HIV-­1  RNA   in   patients   receiving   antiretroviral  
therapy   (El-­Diwany  et   al.,   2017).  Furthermore,   our   data   suggests   that   new  drugs   that  
block   HIV-­1   transcription,   Tat-­mediated   transcriptional   elongation,   or   Rev-­mediated  
preservation  of  unspliced  transcripts  (Mousseau  et  al.,  2015),  would  limit  inflammation,  
and  offer  an  important  addition  to  the  current  anti-­HIV-­1  drug  armamentarium.  
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Data   reporting.   No   statistical  methods  were   used   to   predetermine   sample   size.   The  
experiments   were   not   randomized.   The   investigators   were   not   blinded   to   allocation  
during  experiments  and  outcome  assessment.  
  
Plasmids.  The  plasmids  used  here  were  either  previously  described  or  generated  using  
standard  cloning  methods  (Pertel  et  al.,  2011).  The  full  list  of  plasmids  used  here,  along  
with   their   purpose   and   characteristics,   is   provided   in   Table   1.   All   plasmid  DNAs  with  
complete  nucleotide  sequence  files  are  available  at  www.addgene.com.  
  
Cell   culture.   Cells   were   cultured   at   37°C   in   5%   CO2   humidified   incubators   and  
monitored  for  mycoplasma  contamination  using  the  Lonza  Mycoplasma  Detection  kit  by  
Lonza   (LT07-­318).   HEK293   cells   (ATCC)   were   used   for   viral   production   and   were  
maintained  in  DMEM  supplemented  with  10%  FBS,  20  mM  L-­glutamine  (ThermoFisher),  
25  mM  HEPES  pH  7.2  (SigmaAldrich),  1  mM  sodium  pyruvate  (ThermoFisher),  and  1x  
MEM   non-­essential   amino   acids   (ThermoFisher).   Cytokine   conditioned   media   was  
produced   from   HEK293   cells   stably   transduced   with   pAIP-­hGMCSF-­co   (Addgene  
#74168),   pAIP-­hIL4-­co   (Addgene   #74169),   or   pAIP-­hIL2   (Addgene   #90513),   as  
previously  described  (Pertel  et  al.,  2011).  
  
Leukopaks   were   obtained   from   anonymous,   healthy,   blood   bank   donors   (New   York  
Biologics).   As   per   NIH   guidelines  
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(http://grants.nih.gov/grants/policy/hs/faqs_aps_definitions.htm),  experiments  with  these  
cells   were   declared   non-­human   subjects   research   by   the   UMMS   IRB.   PBMCs   were  
isolated  from  leukopaks  by  gradient  centrifugation  on  Histopaque-­1077  (Sigma-­Aldrich).  
CD14+  mononuclear  cells  were  isolated  via  positive  selection  using  anti-­CD14  antibody  
microbeads  (Miltenyi).  Enrichment  for  CD14+  cells  was  routinely  >98%.    
  
To  generate  DCs  or  macrophages,  CD14+  cells  were  plated  at  a  density  of  1  to  2  x  106  
cells/ml   in   RPMI-­1640   supplemented   with   5%   heat   inactivated   human   AB+   serum  
(Omega  Scientific,   Tarzana,  CA),   20  mM  L-­glutamine,   25  mM  HEPES  pH  7.2,   1  mM  
sodium  pyruvate,  and  1x  MEM  non-­essential   amino  acids   (RPMI-­HS  complete)   in   the  
presence   of   cytokines   that   promote   differentiation.   DCs   were   generated   by   culturing  
monocytes   for  6  days   in   the  presence  of  1:100  cytokine-­conditioned  media  containing  
human   GM-­CSF   and   human   IL-­4.   DC   preparations   were   consistently   >99%   DC-­
SIGNhigh,  CD11chigh,  and  CD14low  by  flow  cytometry.    Macrophages  were  generated  by  
culturing  for  7  days  with  GM-­CSF  conditioned  media   in  the  absence  of   IL-­4,  and  were  
routinely   >99%   CD11b.      CD4+   T   cells   were   isolated   from   PBMCs   that   had   been  
depleted   of   CD14+   cells,   as   above,   using   anti-­CD4   microbeads   (Miltenyi),   and   were  
>99%  CD4+.  CD4+   T   cells  were   then   cultured   in  RPMI-­1640   supplemented  with   10%  
heat   inactivated   FBS,   20   mM   L-­glutamine,   25   mM   HEPES   pH   7.2,   1   mM   sodium  
pyruvate,   1x  MEM  non-­essential   amino   acids   (RPMI-­FBS   complete),   and   1:2000   IL-­2  
conditioned   media.   Cells   from   particular   donors   were   excluded   from   experiments   if  
percent  enrichment  deviated  more   than  5%   from   the  numbers  mentioned  above,  or   if  
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there  was  no  increase  in  activation  markers  in  response  to  control  stimuli  (LPS,  Sendai  
virus,  and  wild-­type  HIV-­1-­GFP).  
    
HIV-­1   vector   production.   HEK293E   cells   were   seeded   at   75%   confluency   in   6-­well  
plates   and   transfected  with   6.25   uL   Transit   LT1   lipid   reagent   (Mirus)   in   250   μL  Opti-­
MEM  (Gibco)  with  2.25  µg  total  plasmid  DNA.  2-­part  HIV-­1  vectors  based  on  HIV-­1-­GFP  
(He  et   al.,   1997)  and  described   in  detail   in  Table  1  were   transfected  at   a  7:1   ratio   in  
terms  of  µgs  of  HIV-­1  plasmid  DNA  to  pMD2.G  VSV  G  expression  plasmid  DNA  (Pertel  
et   al.,   2011).   3-­part   lentivectors   were   produced   by   transfection   of   the   lentivector  
genome,   psPAX2   GagPol   vector,   and   pMD2.G,   at   a   DNA   ratio   of   4:3:1.   These   also  
include   2-­   part   HIV-­1-­GFP   constructs   that   are   mutated   in   such   a   way   as   to   prevent  
GagPol,   Tat,   or   Rev   production.   As   these   would   be   defective   for   viral   production,  
psPAX2  was   included   in   the   transfections   at   the   same   4:3:1   ratio.   VPX-­bearing   SIV-­
VLPs  were  produced  by  transfection  at  a  7:1  plasmid  ratio  of  SIV3+  to  pMD2.G  (Pertel  
et  al.,  2011).  12  hrs  after  transfection,  media  was  changed  to  the  specific  media  for  the  
cells  that  were  to  be  transduced.  Viral  supernatant  was  harvested  2  days  later,  filtered  
through  a  0.45  µm  filter,  and  stored  at  4oC.  
  
Virions   in   the   transfection   supernatant   were   quantified   by   a   PCR-­based   assay   for  
reverse   transcriptase   activity   (Pertel   et   al.,   2011).   5   μl   transfection   supernatant   were  
lysed   in  5  μL  0.25%  Triton  X-­100,  50  mM  KCl,  100  mM  Tris-­HCl  pH  7.4,  and  0.4  U/μl  
RNase   inhibitor   (RiboLock,   ThermoFisher).   Viral   lysate   was   then   diluted   1:100   in   a  
buffer  of  5  mM  (NH4)2SO4,  20  mM  KCl,  and  20  mM  Tris–HCl  pH  8.3.  10  μL  was   then  
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added  to  a  single-­step,  RT  PCR  assay  with  35  nM  MS2  RNA  (IDT)  as  template,  500  nM  
of   each   primer   (5’-­TCCTGCTCAACTTCCTGTCGAG-­3’   and   5’-­
CACAGGTCAAACCTCCTAGGAATG-­3’),  and  hot-­start  Taq  (Promega)  in  a  buffer  of  20  
mM   Tris-­Cl   pH   8.3,   5   mM   (NH4)2SO4,   20   mM   KCl,   5   mM   MgCl2,   0.1   mg/ml   BSA,  
1/20,000  SYBR  Green   I   (Invitrogen),   and   200  μM  dNTPs.   The  RT-­PCR   reaction  was  
carried  out  in  a  Biorad  CFX96  cycler  with  the  following  parameters:  42°C  20  min,  95°C  2  
min,  and  40  cycles  [95°C  for  5  s,  60°C  5  s,  72°C  for  15  s  and  acquisition  at  80°C  for  5  
s].   2   part   vectors   typically   yielded   107   RT   units/µL,   and   3   part   vector   transfections  
yielded  106  RT  units/µL.  
    
Transductions.   106  DCs/mL,   or   5   x   105  macrophages/ml,  were   plated   into  RPMI-­HS  
complete  with  Vpx+  SIV-­VLP  transfection  supernatant  added  at  a  dilution  of  1:6.  After  2  
hrs,  108  RT  units  of  viral  vector  was  added.   In  some  cases,  drugs  were  added   to   the  
culture  media  as  specified  in  Table  2.  In  most  cases,  transduced  DC  were  harvested  for  
analysis  3  days  following  challenge.  For  gene  knockdown  or  for  expression  of  factors  in  
trans,  2  x  106  CD14+  monocytes/mL  were  transduced  directly   following  magnetic  bead  
isolation  with  1:6  volume  of  SIV-­VLPs  and  1:6  volume  of  vector.  When  drug  selection  
was  required,  4  µg/mL  puromycin  was  added  3  days  after  monocyte   transduction  and  
cells  were  selected  for  3  days.    SIV-­VLPs  were  re-­administered  in  all  cases  with  HIV-­1  
or  lentivector  challenge.  For  DCs  in  Tet-­HIV-­1  experiments,  fresh  monocytes  were  SIV-­
VLP  treated  and  co-­transduced  with  rtTA3  and  Tet-­HIV-­1.  DCs  were  harvested  6  days  
later  and  treated  with  indicated  doxycycline  concentrations.  
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For   deoxynucleoside-­assisted   transductions,   DCs   were   plated   at   106   DCs/mL   and  
treated  with  2mM  of  combined  deoxynucleosides  for  2  hrs  before  transduction  with  HIV-­
1.   Deoxynucleosides   were   purchased   from   Sigma-­Aldrich   (2′deoxyguanosine  
monohydrate,   cat#   D0901;;   thymidine,   cat#   T1895;;   2′deoxyadenosine   monohydrate,  
cat#  D8668;;  2′deoxycytidine  hydrochloride,  cat#  D0776).  A  100  mM  stock  solution  was  
prepared  by  dissolving  each  of  the  four  nucleotides  at  100  mM  in  RPMI  1640  by  heating  
the  medium  at  80°C  for  15  min.    
  
CD4+   T   cells   were   stimulated   in   RPMI-­FBS   complete   with   1:2000   hIL-­2   conditioned  
media  and  5  μg/mL  PHA-­P.  After  3  days,  T  cells  were  replated  at  106  cells/mL  in  RPMI-­
FBS  complete  with  hIL-­2.  Cells  were  transduced  with  108  RT  units  of  viral  vector  per  106  
cells   and  assayed  3  days   later.  T   cells  were   co-­transduced  with   rtTA3  and  Tet-­HIV-­1  
every   day   for   3   days   after   PHA   stimulation.   Cells   were   then   replated   in   RPMI-­FBS  
complete   with   hIL-­2.   Transduced   T   cells   were   cultured   for   9   days   with   fresh   media  
added  at   day  5.  After   9   days,   doxycycline  was  added  at   the   indicated   concentrations  
and  assayed  3  days  later.  
  
Non-­HIV-­1   Challenge   Viruses.   Sendai   Virus   Cantell   Strain   was   purchased   from  
Charles  River  Laboratories.  Infections  were  performed  with  200  HA  units/ml  on  DCs  for  
3  days  before  assay  by  flow  cytometry.      
  
Spreading  Infections.    DCs  were  plated  at  106  DCs/mL,  in  RPMI-­HS  complete  media,  
with  or  without  Vpx+  SIV-­VLP  transfection  supernatant  added  at  a  dilution  of  1:6.  After  2  
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hrs,  108  RT  units  of  HEK-­293  transfection  supernatant  of  either  NL4-­3-­GFP  with  JRCSF  
env  (T  tropic)  or  NL4-­3-­GFP  with  JRFL  env  (mac  tropic)  was  added.  Every  3  days  (for  a  
total  of  12  days)  samples  were  harvested  for  detection  of  viral  RT  activity  in  supernatant  
and  flow  cytometry  assessment.        
  
CD4+   T   cells   were   stimulated   in   RPMI-­FBS   complete   with   1:2000   hIL-­2   conditioned  
media  and  5  μg/mL  PHA-­P.  After  3  days,  T  cells  were  replated  at  106  cells/mL  in  RPMI-­
FBS   complete  with   hIL-­2   and   transduced  with   108  RT  units   of  NL4-­3-­GFP  with   JRFL  
(mac  tropic)  or  JRCSF  (T  tropic)  env.  Cells  were  harvested  every  3  days  (for  a  total  of  
12  days)  and  assayed  for  infectivity  and  activation  via  flow  cytometry.  
  
Cytokine   analysis.   Supernatants   from   DCs   were   collected   3   days   following  
transduction  with  HIV-­1-­GFP  or  minimal   lentivector.  Supernatant  was  spun  at  500  x  g  
for  5  mins  and   filtered   through  a  0.45  μm   filter.  Multiplex  soluble  protein  analysis  was  
carried  out  by  Eve  Technologies  (Calgary,  AB,  Canada).  
    
qRT-­PCR.  Total  RNA  was  isolated  from  5  x  105  DCs  using  RNeasy  Plus  Mini  (Qiagen)  
with   Turbo   DNase   (ThermoFisher)   treatment   between   washes.   First-­strand   synthesis  
used   Superscript   III   Vilo   Master   mix   (Invitrogen)   with   random   hexamers.   qPCR   was  
performed   in   20   μL   using   1×   TaqMan   Gene   Expression   Master   Mix   (Applied  
Biosystems),  1  μL  cDNA,  and  1  μL  TaqMan  Gene  Expression  Assays  (ThermoFisher)  
specified  in  Table  3.  Amplification  was  on  a  CFX96  Real  Time  Thermal  Cycler  (Bio-­Rad)  
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using  the  following  program:  95°C  for  10  min  [45  cycles  of  95°C  for  15  s  and  60°C  for  60  
s].  Housekeeping  gene  OAZ1  was  used  as  control  (Pertel  et  al.,  2011).  
    
Flow  cytometry.  105  cells  were  surface  stained   in  FACS  buffer   (PBS,  2%  FBS,  0.1%  
Sodium  Azide),  using  the  antibodies  in  Table  4.  Cells  were  then  fixed  in  a  1:4  dilution  of  
BD   Fixation   Buffer   and   assayed   on   a   BD   C6   Accuri.   BD   Biosciences   Fixation   and  
Permeabilization   buffers   were   utilized   for   intracellular   staining.   Data   was   analyzed   in  
FlowJo.  
  
Sampling.     All   individual  experiments  were  performed  with  biological  duplicates,  using  
cells  isolated  from  two  different  blood  donors.  Flow  cytometry  plots  in  the  figures  show  
representative   data   taken   from   experiments   performed  with   cells   from   the   number   of  
donors  indicated  in  the  figure  legends.      
  
Statistical   Analysis.      Experimental   n   values   and   information   regarding   specific  
statistical  tests  can  be  found  in  the  figure  legends.  The  mean  fluorescence  intensity  for  
all  live  cells  analyzed  under  a  given  condition  was  calculated  as  fold-­change  to  negative  
control/mock.  The  exception   to   this  methodology  was   in  Figures  1g  and  4c  where   the  
percent  infected  cells  was  too  low  to  use  MFI  for  the  bulk  population;;  in  these  cases  MFI  
was   determined   for   the   subset   of   cells   within   the   GFP+   gate.   Significance   of   flow  
cytometry  data  was  determined  via  one-­way  ANOVA.  A  Dunnett’s  post-­test  for  multiple  
comparisons   was   applied,   where   MFI   fold   change   was   compared   to   either   mock  
treatment  or  positive  treatment  depending  on  the  experimental  question.  qRT-­PCR  and  
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luminex  data  was  analyzed  via   two-­way  Anova,  with  Dunnett’s  post-­test  comparing  all  
samples  to  mock.  All  ANOVAs  were  performed  using  PRISM  7.02  software  (GraphPad  
Software,  La  Jolla,  CA).    
  
Data   availability.   The   plasmids   described   in   Table   1,   along   with   their   complete  
nucleotide  sequences,  are  available  at  www.addgene.com.  
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Figure  1.  HIV-­1  transduction  matures  DCs.  
a,  Schematic  of  HIV-­1-­GFP,  with  frameshift  in  env  (red  line)  and  gfp  in  place  of  nef(He  
et  al.,  1997),  and  of   the  minimal   lentivector,  with  self-­inactivating  ΔU3  LTR(Zufferey  et  
al.,  1998)  and  gfp  driven  by   the  SFFV  promoter  (Pertel  et  al.,  2011).  Unless   indicated  
otherwise,   vectors  were   pseudotyped  with   VSV  G   and   cells   were   co-­transduced  with  
SIVMAC251   VLPs   bearing   Vpx.   b,   Flow   cytometry   of   DCs   for   GFP   and   CD86,   after  
treatment  as   indicated.  c,  Flow  cytometry  histograms  for   the   indicated  markers  72  hrs  
after  DC   transduction  with  HIV-­1   (red)   or  mock   (black).  d,  Flow  cytometry   of  DCs   for  
GFP  and  CD86  after   transduction  with  single-­cycle  clones,  HIV-­1NL4-­3,  HIV-­1AD17,  HIV-­
1Z331M-­TF,   or   HIV-­1ZM249M.   e,   Transduction   of   DCs   with   HIV-­2ROD-­GFP,   single-­cycle  
vector.  f,  DC  transduction  with  HIV-­1-­GFP  in  the  absence  of  Vpx  and  the  presence  of  2  
mM  nucleosides.  g,   12   day   spreading   infection   on  DCs,  with  macrophage-­tropic   or   T  
cell-­tropic,   replication-­competent   HIV-­1,   with   or   without   SIV   VLPs.   h,   qRT-­PCR  
quantitation   of   CXCL10   (black),   IFNB1   (gray),   or   IL15   (white)   mRNAs   from   DCs  
transduced   with   HIV-­1-­GFP.   i,   qRT-­PCR   quantitation   of   CXCL10   mRNA   in   DCs  
transduced   with   either   HIV-­1-­GFP   or   minimal   lentivector,   assessed   at   the   indicated  
times  post-­transduction.  j,  Cytokines  in  DC  supernatant  as  assessed  by  luminex,  72  hrs  
after  transduction  with  HIV-­1-­GFP  (black)  or  minimal  lentivector  (gray).  
Shown  are  blood  donor  data  representative  of  n=12  (b),  n=4  (c,  d,  e,  f,  h,  i,  j),  or  n=8  
(g).  To  determine  significance,  the  MFI  of  all   live  cells  for  each  sample  was  calculated  
as   fold-­change   versus   control.   The   exception   being   (g)   where   the  MFI   of   only  GFP+  
cells   was   compared.  When   data   from   each   donor   replicate   within   a   experiment   was  
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combined,  the  difference  in  MFI  for  all  experimental  vs  control  conditions  was  significant  
in   all   cases,   p<0.0001;;   one-­way  ANOVA,  Dunnett’s   post-­test.   qRT-­PCR  and  Luminex  
data   were      mean   +/-­   SD,   p   <   0.0001;;   two-­way   ANOVA,   Dunnett’s   post-­test.  
  
Figure  2.  Native  HIV-­1  RNA  regulation   is  necessary   for  DC  maturation,  but  LTR-­
driven  transcription  is  insufficient  and  coding  sequences  are  not  necessary.  
a,  Assessment   of   GFP   and  CD86   by   flow   cytometry   following   transduction   with,   top,  
HIV-­1-­GFP  in  the  presence  of  5  µM  nevirapine  (RTi),  10  µM  raltegravir  (INi),  or  no  drug,  
and,   bottom,   HIV-­1-­GFP   bearing   mutant   RT-­D185K/D186L   (RTmut)   or   mutant   IN-­
D116A  (INmut).  b,  qRT-­PCR  quantitation  of  CXCL10  mRNA  from  the  same  DCs  as  in  
(a).   c,   DCs   treated   with   1   µM   of   the   TBK1   inhibitor   BX795,   or   expressing   shRNAs  
targeting  either  IRF3  or  luciferase  control  (Pertel  et  al.,  2011),  were  challenged  with  25  
µg/mL  cGAMP  or  HIV-­1-­GFP  and  assayed  by  flow  cytometry  for  CD86  and  ISG15  .  d,  
Flow   cytometry   of   DCs   after   transduction   with  minimal   lentivectors   expressing   codon  
optimized   HIV-­1   genes;;   e,   HIV-­1-­GFP   in   which   translation   was   disrupted   by   two  
frameshifts   in  gag  or   by  mutation   of   the   first   14   AUGs   in  gag;;   f,   HIV-­1-­GFP   bearing  
deletion   mutations   encompassing   gag/pol,   vif/vpr,   vpu/env,   or   nef/U3-­LTR;;   g,   HIV-­1-­
GFP  bearing  mutations  in  tat  or  rev,  co-­transduced  with  both  mutants,  or  co-­transduced  
with  minimal  vector  expressing  tat  and  rev  in  trans;;  or  h,  minimal  lentivector  with  GFP  in  
place  of  gag,  SFFV  promoter  driving  expression  of  tat,  rev,  or  both,  and  repaired  U3  in  
the  3’  LTR;;  the  latter  restores  5’-­LTR-­directed  transcription  to  the  provirus  as  a  result  of  
the   reverse   transcription  strand-­transfer   reactions.  When  an  essential  viral  component  
was   disrupted   within   HIV-­1-­GFP,   the   factor   in   question   was   provided   in   trans,   either  
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/128447doi: bioRxiv preprint first posted online Aug. 7, 2017; 
  28  
during  assembly  in  transfected  HEK293  cells,  or  within  transduced  DCs,  as  appropriate  
(see  Methods).  Shown  are  blood  donor  data  representative  of  n=6  (a,  b,  e,  f),  n=12  (c,  
g,  h),  n=8  (d).  To  determine  significance,  the  MFI  of  individual  flow  cytometry  samples  
was   calculated   as   fold-­change   versus   control.   When   data   from   each   donor   replicate  
within  a  experiment  was  combined,  the  difference  in  MFI  for  all  experimental  vs  control  
conditions  was  significant  in  all  cases,  p<0.0001;;  one-­way  ANOVA,  Dunnett’s  post-­test  
against  HIV-­1-­GFP  for  (a,  c,  d,  h)  or  lentivector  control  for  (e,  f).  qRT-­PCR  data  in  are  
mean+/SD   (p   <   0.0001;;   two-­way   ANOVA,   Dunnett’s   post-­test).  
  
Figure   3.   Rev-­mediated   RNA   export   is   necessary   for   DC   maturation   but   Tat   is  
dispensable.  
a,  Optimized   2xTet   operator   (Das   and  Berkhout,   2016)  was   cloned   into   the   3’LTR   of  
HIV-­1-­GFPΔtat   to   generate   Tet-­HIV-­1;;   the   strand-­transfer   reactions   that   occur   during  
reverse   transcription  generate  a  Tet-­regulated  5’-­LTR   in   the  provirus.  DCs   transduced  
with   Tet-­HIV-­1,   rtTA3,   or   both,   were   treated   for   3   d  with   500   ng/mL   doxycycline   and  
assayed  by   flow   cytometry   for   p24,  GFP,   and  CD86.  b,  DCs   co-­transduced  with  Tet-­
HIV-­1   and   rtTA3   were   treated   with   increasing   concentrations   of   doxycycline.   c,   To  
generate   HIV-­1-­RTE/CTE,   the   RTEm26CTE   element   (Smulevitch   et   al.,   2006)   was  
cloned   in   place   of   nef   in   HIV-­1-­GFPΔrev/ΔRRE.   DCs   were   transduced   with   the  
indicated   vectors   and   assessed   for   p24   and   ISG15   by   flow   cytometry.   d,   DCs   were  
treated  with  25  nM   leptomycin  B,   transduced  with  HIV-­1-­GFP,  and  assessed   for  GFP  
and  ISG15  by  flow  cytometry.  e,  DCs  were  treated  with  25  nM  leptomycin  B,  transduced  
with  HIV-­1-­GFP  or   infected  with  Sendai   virus   (SeV),  and  assessed   for   ISG15  by   flow  
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cytometry.  Shown  are  blood  donor  data  representative  of  n=10  (a,  c),  n=4  (b),  n=6  (d,  
e).   To   determine   significance,   the   MFI   of   individual   flow   cytometry   samples   was  
calculated  as  fold-­change  versus  control.  When  data  from  each  donor  replicate  within  a  
experiment   was   combined,   the   difference   in   MFI   for   all   experimental   vs   control  
conditions  was  significant  in  all  cases,  p<0.0001;;  one-­way  ANOVA,  Dunnett’s  post-­test  
against  dox  negative  control  for  (a,  b)  or  HIV-­1-­GFP  for  (c,  d,  e).    
  
Figure   4.   Innate   immune   activation   in  macrophages   and   CD4+   T   cells   by   HIV-­1  
proviral  transcription.  
a,   Macrophages   and   CD4+   T   cells   were   transduced   with   HIV-­1-­GFP   and   assayed   3  
days  later  for  the  indicated  activation  markers.  b,  DCs,  macrophages,  and  CD4+  T  cells  
were   challenged   with   HIV-­1-­GFP   or   the   indicated   mutants.   When   an   essential   viral  
component   was   disrupted   within   HIV-­1-­GFP,   the   factor   in   question   was   provided   in  
trans  during  assembly  in  transfected  HEK293  cells,  as  appropriate  (see  Methods).  The  
upper  panel  shows  flow  cytometry  of  the  DCs  for  GFP  and  CD86.  The  histograms  show  
CD86   for   DCs   and   macrophages   or   MX1   for   CD4+   T   cells.   c,   12   day   spreading  
infections   on   CD4+   T   cells   with   either  macrophage-­tropic   or   T   cell-­tropic,   replication-­
competent  HIV-­1.   d,  CD4+   T   cells  were   stimulated   for   3   days  with  PHA  and   IL2,   and  
transduced  with  Tet-­HIV-­1  and  rtTA3.  Cells  were  then  cultured  without  stimulation  for  9  
days.  Doxycycline  was  then  added  at  the  indicated  concentrations.  Cells  were  assayed  
for  GFP  and  MX1  3  days  later.  Shown  are  blood  donor  data  representative  of  n=6  (a),  
n=4  (b,  c,  d).  To  determine  significance,   the  MFI  of   individual   flow  cytometry  samples  
was  calculated  as  fold-­change  versus  control.  The  exception  being  (c)  where  the  MFI  of  
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only   GFP+   cells   was   compared.   When   data   from   each   donor   replicate   within   a  
experiment   was   combined,   the   difference   in   MFI   for   all   experimental   vs   control  
conditions  was  significant  in  all  cases,  p<0.0001;;  one-­way  ANOVA,  Dunnett’s  post-­test  
against  lentivector  control  for  (a,  b,  c)  or  dox  control  for  (d).  
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Table  1.  Plasmids  used  in  this  study.  
Plasmid  Name   Purpose   Notes   Addgene  code  #  




“HIV-­1-­GFP”  in  the  manuscript.  HIV-­1  NL4-­3  
in  pBluescript,  flanking  host  sequences  
deleted,  frameshift  in  env,  eGFP  in  place  of  




HIV-­1  clade  B  
molecular  clone  
Molecular  clone  of  NL4-­3  with  deletion  of  79  
nucleotides  following  the  Env  signal  peptide  




HIV-­1  clade  B  
molecular  clone  
Molecular  clone  of  transmitted/founder  virus  
HIV-­1AD17  (Parrish  et  al.,  2013)  with  deletion  of  
79  nucleotides  following  the  Env  signal  
peptide  and  eGFP  in  place  of  nef  
pending  
pUC57mini  Z331M-­
TF  Δenv  eGFP  
HIV-­1  clade  C  
molecular  clone  
Molecular  clone  of  transmitted/founder  virus  
HIV-­1Z331M-­TF  (Deymier  et  al.,  2015)  with  
deletion  of  79  nucleotides  following  the  Env  





HIV-­1  clade  C  
molecular  clone  
Molecular  clone  of  transmitted/founder  virus  
HIV-­1ZM249M  (Salazar-­Gonzalez  et  al.,  2009)  
with  deletion  of  79  nucleotides  following  the  
Env  signal  peptide  and  eGFP  in  place  of  nef  
pending  




Molecular  clone  of  HIV-­2ROD.  Contains  
frameshift  in  env  and  eGFP  in  place  of  Nef   pending  
pMD2.G   VSV  G   Pseudotype  HIV-­1  vectors  with  VSV  G   12259  
psPAX2   HIV-­1  gag-­pol   "3-­part"  lentivector  or  for  complementation  of  assembly-­incompetent  HIV-­1  vectors   12260  





Includes  cis-­acting  elements  required  for  
reverse  transcription  and  integration,  psi  RNA  
packaging  element,  RRE,  cPPT,  PPT,  
mutation  in  the  3’LTR  U3  that  eliminates  LTR-­
based  transcription,  and  SFFV  promoter  to  
express  genes  of  interest.  
90996  
pALPS  eGFP   eGFP  lentivector   Encodes  eGFP   pending  
pALPS  gag   gag  lentivector   Encodes  codon  optimized  NL4-­3  gag   pending  
pALPS  env   env  lentivector   Encodes  codon  optimized  JR-­CSF  env   pending  
pALPS  tat   tat  lentivector   Encodes  codon  optimized  NL4-­3  tat   pending  
pALPS  rev   rev  lentivector   Encodes  codon  optimized  NL4-­3  rev   pending  
pALPS  vif   vif  lentivector   Encodes  codon  optimized  NL4-­3  vif   pending  
pALPS  vpr   vpr  lentivector   Encodes  codon  optimized  NL4-­3  vpr   pending  
pALPS  vpu   vpu  lentivector   Encodes  codon  optimized  NL4-­3  vpu   pending  
pALPS  tat-­P2A-­rev   tat  and  rev  lentivector  
Lentivector  expressing  codon  optimized  NL4-­3  
tat  and  rev  linked  by  P2A  peptide  coding  
sequence  (GSGATNFSLLKQAGDVEENPGP)  
pending  
pBS  NL4-­3  envFS  
eGFP  RT-­
D185K/D186L  (De  
RT  mutant   pBS  NL4-­3  env
FS  eGFP  with  mutation  that  
disrupts  RT  catalytic  activity       pending  
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Iaco  and  Luban,  
2011)  
pBS  NL4-­3  envFS  
eGFP  IN-­D116A  
(De  Iaco  and  
Luban,  2011)  
IN  mutant   pBS  NL4-­3  env
FS  eGFP  with  mutation  that  
disrupts  IN  catalytic  activity     pending  
pBS  NL4-­3  envFS  
eGFP  PR-­D25A  
(De  Iaco  and  
Luban,  2011)  
PR  mutant   pBS  NL4-­3  env
FS  eGFP  with  mutation  that  
disrupts  Protease  catalytic  activity   pending  
pALPS  puro  
miR30-­L1221  
(Pertel  et  al.,  2011)  
Luciferase  
knockdown  
negative  control  for  knockdowns  
target  site:  CTTGTCGATGAGAGCGTTTGT   pending  
pALPS  puro  
miR30-­IRF1  (Pertel  
et  al.,  2011)  
IRF1  knockdown   Target  site  TTGCTCTTAGCATCTCGGCTG   pending  
pALPS  puro  
miR30-­IRF3  (Pertel  
et  al.,  2011)  
IRF3  knockdown   Target  site  ATCAGATCTACAATGAAGGGC   pending  
pALPS  puro  
miR30-­IRF5  (Pertel  
et  al.,  2011)  
IRF5  knockdown   Target  site  TATTTCCCTGTCTCCTTGGCC   pending  
pALPS  puro  
miR30-­IRF7  (Pertel  
et  al.,  2011)  
IRF7  knockdown   Target  site  ATAAGGAAGCACTCGATGTCG   pending  
pALPS  puro  
miR30-­IRF9  (Pertel  
et  al.,  2011)  
IRF9  knockdown   Target  site  AATTATCACAAAGAGGACAGG   pending  
pALPS  puro  
miR30-­STAT1  
(Pertel  et  al.,  2011)  
STAT1  
knockdown   Target  site  ATATCCAGTTCCTTTAGGGCC   pending  
pALPS  puro  
miR30-­STAT2  
(Pertel  et  al.,  2011)  
STAT2  
knockdown   Target  site  TTTAAGTTCCACAGACTTGGA   pending  
pALPS  puro  
miR30-­TAK1  
((Pertel  et  al.,  
2011)  





GFP  at  gag  start  
SFFV  promoter  
Repaired  U3  allows  LTR-­based  transcription  
by  the  provirus  with  GFP  as  a  marker  for  





U3+  lentivector    
GFP  at  gag  start  
SFFV-­tat  
LTR  drives  GFP  and  internal  SFFV  promoter  





GFP  at  gag  start  
SFFV-­rev  
LTR  drives  GFP  and  internal  SFFV  promoter  







LTR  drives  GFP  and  internal  SFFV  promoter  





1st  frameshift  is  CG  nucleotide  insertion  in  MA  
at  nt  832.    2nd  is  a  CTAG  addition  in  CA  at  nt   pending  
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All  ATGs  from  the  start  of  gag  to  NC  mutated  
to  ATC  except  the  first  which  was  mutated  to  
ACG  
pending  
pBS  NL4-­3  envFS  
eGFP  Δgag/pol   gag-­pol  deletion  
Deletion  from  the  start  of  gag  until  229  bases  
before  the  cPPT   pending  
pNL4-­3  envFS  
eGFP  Δvif/vpr   vif/vpr  deletion  
Deletion  from  NL4-­3  nt  5582-­6199  
encompassing  Vif  and  Vpr  coding  sequence   pending  
pNL4-­3  envFS  
eGFP  Δvpu/env   vpu/env  deletion  
Deletion  from  NL4-­3  nt  6054-­7489  
encompassing  all  of  vpu  and  env  until  before  
the  RRE  
pending  
pBS  NL4-­3  envFS  
eGFP  Δnef/U3   nef/U3  deletion  
Deletion  from  NL4-­3  nt  8911-­9022  and  9088-­
9377.    This  deletes  nef  and  U3  LTR  
sequences  
pending  
pBS  NL4-­3  envFS  
eGFP  5'CMV  Δtat  
HIV-­1  with  
inactivating  
mutations  in  tat  
tat  ATG-­>ACG  (silent  in  vpr  reading  frame),  nt  
78  mutated  T-­>G  to  change  Tyr  to  stop  codon,  
nt  116  mutated  T-­>C  to  disrupt  Met,  5'LTR  
replaced  with  CMV-­R-­U5  from  pALPS  for  tat-­
independent  transcription  in  HEK293E  cells.  
pending  




mutations  in  rev  
All  mutations  in  rev  are  silent  with  respect  to  
the  tat  reading  frame.  Start  ATG-­>ACG  and  
nts  68-­71  were  mutated  AGC-­>TCA  to  change  
tyrosine  to  a  stop.  
pending  
pBS  NL4-­3  envFS  
eGFP  5'CMV  Δtat  
ΔTARx2_d2TetOp(





2xTet  Operator  inserted  between  NFkB  and  
Sp1  sites  in  U3  of  HIV-­1  Δtat  with  5'  CMV-­R-­










rtTA3  lentivector     Codon  optimized  rtTA3  used  in  trans  with  Tet  inducible  HIV-­1   pending  
pSC101  NL4-­3  
envFS  Δrev  ΔRRE  
RTEm26CTE(Smul




HIV-­1  ΔRev  was  cloned  into  pSC101  and  
modified  to  include  an  RTEm26CTE  element  
in  order  to  utilize  the  NXF1  RNA  export  
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Table  2.  Drugs  and  reagents.  
Drug   Action   Source   Working  concentration  
HIV-­1  DC  
maturation  
Doxycycline   rtTA3  activator   Sigma  (D9891)   10-­1000  ng/mL   -­  
cGAMP   STING  activator   Invivogen  (tlrl-­nacga23)   25  µg/mL   -­  
PHA-­P   T  cell  mitogen   Sigma  (L1668)   5  μg/mL   -­  
2′deoxyguanosine  
monohydrate  
For  nucleoside  assisted  
transductions   Sigma  (D0901)   2  mM   -­  
2’  deoxythymidine   For  nucleoside  assisted  transductions   Sigma  (T1895)   2  mM   -­  
2′deoxyadenosine  
monohydrate  
For  nucleoside  assisted  
transductions   Sigma  (D8668)   2  mM   -­  
2′deoxycytidine  
hydrochloride  
For  nucleoside  assisted  
transductions   Sigma  (D0776)   2  mM   -­  
Sendai  Virus  (SeV)  
Cantell  strain   Challenge  virus  
Charles  River  Labs  
(VR-­907)   200  HA  units/mL   -­  
Nevirapine   Reverse  transcriptase  inhibitor  
NIH  AIDS  reagent  
program  (4666)   5  µM   Inhibits  
Raltegravir   Integrase  inhibitor   NIH  AIDS  reagent  program  (11680)   10  µM   Inhibits  
Leptomycin   CRM1  inhibitor   Invivogen    (tlrl-­lep)   25  nM   Inhibits  
Cyclosporin  A   Cyclophilin  A  inhibitor   Sigma  (30024)   5  µM   No  effect  
GW-­5075   c-­Raf   Sigma  (G6416)   1,  5,  25  µM   No  effect  
BAY11-­7082   IkB-­a  Inhibitor   Invivogen    (tlrl-­b82)   1,  2.5,  10  µM   No  effect  
U0126   MEK1  and  MEK2  Inhibitor  
Invivogen  (tlrl-­
u0126)   10,  25,  50  µM   No  effect  
SB203580   p38  MAP  Kinase  Inhibitor  
Invivogen  (tlrl-­
sb20)   1,  2.5,  10  µM   No  effect  
MCC950   NLRP3-­inflammasome  inhibitor  
Invivogen  (inh-­
mcc)   1,  2.5,  10  µM   No  effect  
SP600125   JNK  Inhibitor   Invivogen  (tlrl-­sp60)   10,  25,  100  µM   No  effect  
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Z-­VAD-­FMK   Pan-­Caspase  Inhibitor   Invivogen    (tlrl-­vad)   1,  5,  20  µM   No  effect  
NQDI-­1   ASK1  inhibitor   Sigma  (SML0185)   1,  10,  100  µM   No  effect  
ISRIB   eIF2a  phosphorylation  inhibitor   Sigma  (SML0843)   1,  10,  100  µM   No  effect  
VX-­765   Caspase  1  inhibitor   Invivogen  (inh-­vx765i)   1,  10,  100  µM   No  effect  
Dexamethasone   NF-­kB  and  MAPK  inhibitor  
Invivogen  
  (tlrl-­dex)   10,  100,  1000  nM   No  effect  
Chloroquine   inhibitor  of  endosomal  acidification  
Invivogen  
  (tlrl-­chq)   1,  10,  100  µM   No  effect  
Amlexanox   TBK1/IKKε  inhibitor   Invivogen  (inh-­amx)   1,  10,  100  ug/mL   No  effect  
BX795   TBK1/IKKε  inhibitor   Invivogen    (tlrl-­bx7)   0.5,  1,  2  µM   No  effect  
NG25  trihydrochloride   TAK1  &  LYN,  MAP4K2  and  Abl  inhibitor   Sigma  (SML1332)  
50,  100,  500,  
1000  nM   No  effect  
5Z-­7-­Oxozeaenol   TAK1  &  MAP4K2  inhibitor   Sigma  (O9890)  
50,  100,  500,  
1000  nM   No  effect  
C16   PKR  inhibitor   Sigma  (I9785)   1  µM   No  effect  
2AP   PKR  inhibitor   Invivogen    (tlrl-­apr)   5  µM   No  effect  
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Table  3.  qRT-­PCR  probes.  
RNA  Target   Taqman  probe  ID#  
CXCL10   Hs00171042_m1  
IFNB1   Hs01077958_s1  
IL15   Hs01003716_m1  
OAZ1   Hs00427923_m1  
ACTB   Hs01060665_g1  
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Table  4.  Antibodies  used  in  this  study.  
Target  antigen   Clone   Fluorophore   Source  
CD80   2D10   PE,  APC   Biolegend  
CD86   IT2.2   PE,  APC   Biolegend  
CD40   HB14   APC   Biolegend  
HLA-­DR   L249   PerCP,  APC   Biolegend  
CD83   HB15e   FITC,  APC   Biolegend  
CCR7   G043H7   PE   Biolegend  
CD141   M80   PE   Biolegend  
ISG15   #851701   PE,  APC   R&D  Systems  
MX1   EPR19967   N/A   Abcam  
IFIT   OTI3G8   N/A   Abcam  
p24   KC57   FITC,  PE   BeckmanCoulter  
CD1a   HI149   FITC,  PerCP   Biolegend  
CD1c   L161   PE   Biolegend  
CD14   HCD14   FITC,  Pe-­Cy7   Biolegend  
CD11b   ICRF44   PE   Biolegend  
CD11c   3.9   PE,  PE-­Cy7,  APC   Biolegend  
CD209  (DC-­SIGN)   9E9A8   APC   Biolegend  
CXCL10   JO34D6   PE   Biolegend  
HLA-­ABC   W6/32   FITC   Biolegend  
CD3   OKT3   FITC,  APC,  BV650   Biolegend  
CD4   OKT4   FITC,  APC,  Alexa700   Biolegend  
Mouse-­IgG   Poly4053   PE,  APC   Biolegend  
Rabbit-­IgG   Poly4064   PE,  AlexaFluor647   Biolegend  
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